These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 26742943)
1. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943 [TBL] [Abstract][Full Text] [Related]
2. Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia. Ansari AS; Kucharski C; Kc R; Nisakar D; Rahim R; Jiang X; Brandwein J; Uludağ H Acta Biomater; 2024 Oct; 188():297-314. PubMed ID: 39236794 [TBL] [Abstract][Full Text] [Related]
3. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Ladikou EE; Chevassut T; Pepper CJ; Pepper AG Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579 [TBL] [Abstract][Full Text] [Related]
4. Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. Landry B; Aliabadi HM; Samuel A; Gül-Uludağ H; Jiang X; Kutsch O; Uludağ H PLoS One; 2012; 7(8):e44197. PubMed ID: 22952927 [TBL] [Abstract][Full Text] [Related]
5. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis. Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086 [TBL] [Abstract][Full Text] [Related]
6. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566 [TBL] [Abstract][Full Text] [Related]
9. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment. Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122 [TBL] [Abstract][Full Text] [Related]
10. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia]. Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448 [TBL] [Abstract][Full Text] [Related]
11. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. Ansari AS; K C R; Morales LC; Nasrullah M; Meenakshi Sundaram DN; Kucharski C; Jiang X; Brandwein J; Uludağ H J Control Release; 2024 Mar; 367():821-836. PubMed ID: 38360178 [TBL] [Abstract][Full Text] [Related]
12. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632 [TBL] [Abstract][Full Text] [Related]
14. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. Chen Z; Teo AE; McCarty N Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264 [TBL] [Abstract][Full Text] [Related]
15. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. Kremer KN; Peterson KL; Schneider PA; Meng XW; Dai H; Hess AD; Smith BD; Rodriguez-Ramirez C; Karp JE; Kaufmann SH; Hedin KE J Biol Chem; 2013 Aug; 288(32):22899-914. PubMed ID: 23798675 [TBL] [Abstract][Full Text] [Related]
16. Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia. Wang Y; Xie Y; Williams J; Hang Y; Richter L; Becker M; Amador C; Oupický D; Hyde RK Cancer Gene Ther; 2020 Feb; 27(1-2):45-55. PubMed ID: 31028289 [TBL] [Abstract][Full Text] [Related]
17. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination. Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815 [TBL] [Abstract][Full Text] [Related]
18. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398 [TBL] [Abstract][Full Text] [Related]
19. [Effects of anti-CXCR4 monoclonal antibody on adhesion and proliferation of human acute myelocytic leukemia cell line HL-60]. Wei L; Kong PY; Chen XH; Peng XG; Zeng DF; Chang C; Yang WB; Liu H; Liu L; Wang QY; Zhang Y Ai Zheng; 2004 Nov; 23(11):1273-7. PubMed ID: 15522172 [TBL] [Abstract][Full Text] [Related]
20. A Dual-Function LipoAraN-E5 Coloaded with Wang X; Wang X; Su J; Wang D; Feng W; Wang X; Lu H; Wang A; Liu M; Xia G ACS Nano; 2024 Oct; 18(41):27917-27932. PubMed ID: 39364559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]